MEI's ME-344 inhibits tumor cell proliferation in breast cancer trial

MEI Pharma Inc. (NASDAQ:MEIP) said ME-344 plus Avastin bevacizumab led to greater inhibition of

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE